Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen
- PMID: 15096801
- DOI: 10.1097/00002030-200404300-00006
Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen
Abstract
Objectives: To evaluate the immunogenicity of sequence-modified HIV env and gag in baboons using DNA prime and protein boost strategy.
Methods: Synthetic sequence-modified HIV gene cassettes were constructed that expressed three different forms of Env proteins, gp140, gp140mut and gp140TM, plus or minus a mutation in the protease-cleavage site. These plasmids were used to immunize baboons (Papio cynocephalus). A group of baboons was also immunized with both env and gag DNA followed by p55Gag virus-like particles (VLP) boost.
Results: Modest antibody responses and low or no lymphoproliferative responses were observed following multiple DNA immunizations. In contrast, strong antibodies and substantial antigen-specific lymphoproliferative responses were seen following booster immunizations with oligomeric Env protein (o-gp140US4) in MF59. Neutralizing antibody responses were scored against T cell line adapted HIV-1 strains after the protein boosters, but neutralizing responses were low or absent against homologous and heterologous primary isolate strains. In the group receiving both gag and env vaccines, modest antigen-specific antibody and lymphoproliferative responses were scored after the DNA immunizations; these responses were enhanced several-fold upon boosting with the VLP preparations. The addition of Gag antigen did not interfere with Env-specific antibody responses, but there was a negative effect on the levels of Env-specific lymphoproliferation.
Conclusions: These results highlight the importance of improving the potency of HIV DNA vaccines by enhanced DNA delivery and prime-boost vaccine technologies to generate more robust immune responses in larger animal models. In addition, care must be taken when immunizations with Env and Gag antigens are performed together.
Similar articles
-
Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.Vaccine. 2012 Feb 27;30(10):1830-40. doi: 10.1016/j.vaccine.2011.12.131. Epub 2012 Jan 9. Vaccine. 2012. PMID: 22234262 Free PMC article.
-
Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.J Virol. 2019 Apr 3;93(8):e02155-18. doi: 10.1128/JVI.02155-18. Print 2019 Apr 15. J Virol. 2019. PMID: 30760570 Free PMC article.
-
Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees.AIDS Res Hum Retroviruses. 1993 May;9(5):395-404. doi: 10.1089/aid.1993.9.395. AIDS Res Hum Retroviruses. 1993. PMID: 8318268
-
Virus-like particle and DNA-based candidate AIDS vaccines.Vaccine. 2003 Jan 30;21(7-8):638-43. doi: 10.1016/s0264-410x(02)00572-8. Vaccine. 2003. PMID: 12531332 Review.
-
Developing DNA vaccines against immunodeficiency viruses.Curr Top Microbiol Immunol. 1998;226:161-73. doi: 10.1007/978-3-642-80475-5_10. Curr Top Microbiol Immunol. 1998. PMID: 9479841 Review. No abstract available.
Cited by
-
Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.J Virol. 2005 Mar;79(6):3358-69. doi: 10.1128/JVI.79.6.3358-3369.2005. J Virol. 2005. PMID: 15731230 Free PMC article.
-
Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.Vaccine. 2007 Feb 9;25(8):1398-408. doi: 10.1016/j.vaccine.2006.10.046. Epub 2006 Nov 7. Vaccine. 2007. PMID: 17113201 Free PMC article.
-
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers.Vaccine. 2008 Jul 23;26(31):3947-57. doi: 10.1016/j.vaccine.2007.12.060. Vaccine. 2008. PMID: 18724414 Free PMC article. Clinical Trial.
-
Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters.BMC Immunol. 2006 Oct 31;7:25. doi: 10.1186/1471-2172-7-25. BMC Immunol. 2006. PMID: 17076905 Free PMC article.
-
Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.J Virol. 2013 May;87(9):5151-60. doi: 10.1128/JVI.03178-12. Epub 2013 Feb 28. J Virol. 2013. PMID: 23449790 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources